深圳新風和睦家醫院每年香港患者人次達1.7萬 目標佔比達五成
太古(00019.HK)有份投資的深圳新風和睦家醫院,至今營運超過三年,香港患者每年診療人次達1.7萬,佔整體病人約三成。上月港人門診量比去年同期增加3倍,而腫瘤科病人中,本港病人更佔八成。
院方表示,醫院去年8月起參加有關的大灣區試點計劃,65歲或以上香港長者有近5000就診人次,主要是身體檢查、眼科檢查、高血壓或糖尿病的慢性病跟進、外科檢查等,部分檢查患有前列腺、白內障、膝關節等長者,有需要亦入院接受手術。
醫院屬港資私立醫院,設於深圳福田區,腫瘤科副主任表示,醫院的同類標靶藥費用比香港便宜。醫院正使用3款內地創新藥,部分藥物價錢只是進口同類藥的四成多。至於通過香港、深圳、廣州醫生聯合會診,有助大幅縮短診療周期,因此在跨境癌症醫療服務上有優勢。
院方指需要在內地聘請高質素的醫生,會集中在北京、上海、廣州招募。目標未來三到五年,港人患者佔比增至五成,但強調並非與香港私家醫院爭生意,而是作為公立醫院的補充。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.